supp.fit

Vitamin C, Copper and Beta-Carotene: study protocols

8 study groups took Vitamin C together with Copper and Beta-Carotene. These are the doses the studies gave. They are not a recommendation.

Vitamin C: what the research found →

Dose per serving from research: Vitamin C

8 study groups in 4 studies say how much Vitamin C participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 250 mg to 500 mg, 88% of 8 study groups.

Daily doseStudy groups
250 mg or less
1
250 mg to 500 mg
7

Dose per serving from research: Beta-Carotene

8 study groups in 4 studies say how much Beta-Carotene participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 10 mg to 25 mg, 88% of 8 study groups.

Daily doseStudy groups
10 mg or less
1
10 mg to 25 mg
7

Commonly used together

8 of 8 study groups took Vitamin C, Copper and Beta-Carotene with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Vitamin E
8
Zinc
8

8 study groups

Study
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8
2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye
500 mg2 mg15 mg8 years—
No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38
2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years
500 mg2 mg15 mg9 years—
Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study
2014 · softgel half-dose (single softgel) · Healthy adults aged 18–45 years, women and men
226 mg—8.6 mg1 day15
Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study
2014 · softgel full-dose (two softgels) · Healthy adults aged 18–45 years, women and men
452 mg—17.2 mg1 day15
Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study
2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men
452 mg—17.2 mg1 day15
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration
500 mg2 mg15 mg5 years—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation
500 mg2 mg15 mg5 years—
Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation
500 mg—15 mg5 years—